WE INVITED DR eMALICK NJIE FOUNDER AND CEO OF ECOTONE. WE SPOKE AT LENGTH ON THE BASIC PRINCIPLES OF AI AND WE WENT ON TO EXPLORE THE USE CASES OF AI IN MEDICINE. WE ALSO EXPLORED THE EXTREMITIES OF AI AND WHY IT IS IMPORTANT FOR REGULATORS TO GET AHEAD OF IT.
Brief on Dr eMalick Njie:
Dr Njie, who previously served as a senior scientist in a Nobel Prize-winning laboratory at Columbia University, was early to recognize the immense potential of AI. In 2016, he established a genetics and AI company called Genetic Intelligence (GI) that went on to win the NSF SBIR and achieved a valuation of $85 million, following which he exited the company.
Over the next several years, Dr Njie devoted himself to privately developing AI that aims to bring the same level of clarity to our understanding of genetics and diseases as ChatGPT has done for natural language. During this period, he also explored other interests, such as establishing the think tank studio NeuroStorm Studios (NSS) to delve into the future of medicine. NSS partnered with Weil Cornel Medicine to concentrate on digital medicines and successfully conducted a pre-clinical trial that explored the potential of algorithms in visual space to alleviate the tremors of Parkinson’s patients. NSS is continuing to explore algorithms as a novel form of non-invasive medicine. The FDA has recently recognized such medications as Software as Medical Devices (SaMD).
Dr Njie also played a vital role in launching Prisms, an education company, as an AI Business Advisor. He assisted in assembling the early team and winning the NSF SBIR. Prisms has recently raised a Series A from Andreessen Horowitz and has garnered attention in VentureBeat and Business Insider.
Currently, Dr Njie is dedicated to Ecotone, a company he founded based on the aforementioned AI. Ecotone's mission is to develop precision medicines that cure approximately 10,000 inherited diseases that have been largely overlooked by the pharmaceutical industry. Ecotone is currently in selective stealth mode and open to discussions with investors and talent interested in advancing medicine to the AI era.